Cryoservice manager runs the extra mile for Cancer Research

David Bryant completes 145-mile Grand Union Canal Run from Birmingham to London

The 145-mile Grand Union Canal Run is generally acknowledged as Britain’s longest continual race. Starting in Broad Street, Birmingham and finishing in Little Italy, London, competitors have to complete the race in 45 hours.

David Bryant, Cryoservice's business manager for science and industry, took 39 hours 15 minutes to complete the distance, running without sleep or a reasonable break.

‘The race is extremely challenging with only 40% of the starting line up normally finishing, so a hard training regime was required even to be in with a chance of reaching London,’ he said.

‘What kept me going was the knowledge that so many people had sponsored me and that the money raised would be going to a good cause.’

Bryant raised £3,350 for Cancer Research and came 16th.

Cryoservice, a supplier of specialist gases for science, leisure and industry, based in Worcester, UK, is a long-term business partner of Cancer Research UK and was recently short-listed for Supplier of the Year award, in recognition of its commitment and support of the organisation.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery

Autoinjector platforms: optimising device selection and unlocking manufacturing efficiency for injectable pipelines

Owing to ageing populations, the increased prevalence of chronic disease and additional pressure on global healthcare systems, among other factors, the market for drug delivery devices for self-administration (autoinjectors) is growing
Ingredients

Lubrizol to showcase game-changing excipients and nutraceutical ingredients at CPHI Frankfurt

Lubrizol partners with pharmaceutical and nutraceutical companies to develop innovative solutions that improve patient outcomes and offer consumer benefits
Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence

OMass and Genentech to develop and commercialise therapies for inflammatory bowel disease

The collaboration leverages OMass’ Odyssion platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease
Research & Development

Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent

Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Debunking the myths of HPMC adoption

Adopting new products, formulations and ways of working can be a challenge for industries as regulated as pharmaceuticals, writes Dr Subhashis Chakraborty, General Manager, Head of Global Product Management, at ACG Capsules
Drug Delivery

Breaking barriers: enhancing the bioavailability of orally delivered TPDs

It’s been said that nothing vast enters the realm of mortals without a curse. Such is the case with targeted protein degraders (TPDs), now one of the fastest-growing frontiers in oral solid dose pharmaceuticals
Subscribe now